References
- Senzolo M, Garcia-Tsao G, García-Pagán J. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol. 2021;75:442–453.
- Violi F, Corazza G, Caldwell S, et al. Incidence and recurrence of portal vein thrombosis in cirrhotic patients. Thromb Haemost. 2019;119(3):496–9. doi: 10.1055/s-0038-1676981
- Garcia-Tsao G, Abraldes J, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatol. 2017;65(1):310–335. doi: 10.1002/hep.28906
- de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. doi: 10.1016/j.jhep.2021.12.022
- Kwon J, Koh Y, Yu S, et al. Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: efficacy and the risk of hemorrhagic complications. Thromb Res. 2018;163:71–6. doi:10.1016/j.thromres.2018.01.032
- Pettinari I, Vukotic R, Stefanescu H, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol. 2019;114:258–266. doi: 10.1038/s41395-018-0421-0
- La Mura V, Braham S, Tosetti G, et al. Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2018;16(7):1146–1152. doi: 10.1016/j.cgh.2017.10.016
- Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. doi: 10.1111/j.1538-7836.2005.01204.x
- Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7. doi: 10.1136/gut.2004.042796
- Intagliata N, Caldwell S, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterol. 2019;156(6):1582–1599. doi: 10.1053/j.gastro.2019.01.265
- Senzolo M, Piano S, Shalaby S, et al. Comparison of fondaparinux and low-molecular-weight heparin in the treatment of portal vein thrombosis in cirrhosis. Am J Med. 2021;134(10):1278–1285. doi: 10.1016/j.amjmed.2021.05.013
- Turco L, de Raucourt E, Valla D, et al. Anticoagulation in the cirrhotic patient. JHEP Rep. 2019;1(3):227–39. doi: 10.1016/j.jhepr.2019.02.006
- Guerrero A, Campo L, Piscaglia F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis. J Hepatol. 2023;79(1):69–78. doi: 10.1016/j.jhep.2023.02.023
- Loffredo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterol. 2017;153(2):480–487.
- Maruyama H, Okugawa H, Takahashi M, et al. De Novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108(4):568–74. doi: 10.1038/ajg.2012.452
- Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175(9):1474–80. doi: 10.1001/jamainternmed.2015.3184
- Søgaard K, Darvalics B, Horváth-Puhó E, et al. Survival after splanchnic vein thrombosis: a 20-year nationwide cohort study. Thromb Res. 2016;141:1–7.
- Yerdel M, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantat. 2000;69(9):1873–1881. doi: 10.1097/00007890-200005150-00023
- Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterol. 2012;143(5):1253–1260. doi: 10.1053/j.gastro.2012.07.018